APA (7th ed.) Citation

J, D. G., J, V. M., JF, V., L, D., AP, M., P, V., . . . E, T. (2016). Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT). PloS one, 11(3), e0147599. https://doi.org/10.1371/journal.pone.0147599

Chicago Style (17th ed.) Citation

J, De Grève, et al. "Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT)." PloS One 11, no. 3 (2016): e0147599. https://doi.org/10.1371/journal.pone.0147599.

MLA (9th ed.) Citation

J, De Grève, et al. "Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT)." PloS One, vol. 11, no. 3, 2016, p. e0147599, https://doi.org/10.1371/journal.pone.0147599.